Experimental Chikungunya Vaccine is Safe and Well-Tolerated in Early Trial | NIH: National Institute of Allergy and Infectious Diseases

Experimental Chikungunya Vaccine is Safe and Well-Tolerated in Early Trial | NIH: National Institute of Allergy and Infectious Diseases

Friday, April 17, 2020 Experimental Chikungunya Vaccine is Safe and Well-Tolerated in Early Trial The chikungunya virus, which is found throughout tropical areas of the world, can cause intense pain and joint inflammation. Unfortunately, this mosquito-borne virus currently has no cure or vaccine. In a paper published this week in JAMA, NIAID researchers describe a Phase 2 trial showing that an experimental chikungunya vaccine is both safe and well-tolerated, and shows promise for future trials.